Comparing models and experimental structures of the GPR101 receptor: Artificial intelligence yields highly accurate models
- PMID: 40472416
- PMCID: PMC12354288
- DOI: 10.1016/j.jmgm.2025.109103
Comparing models and experimental structures of the GPR101 receptor: Artificial intelligence yields highly accurate models
Abstract
Experimental structures solved through cryo-electron microscopy have recently been published for GPR101, a G protein-coupled receptor (GPCR) implicated in the genetic condition X-linked acrogigantism (X-LAG). Here, we compared these experimental structures with computational models that we previously published, including our internally developed homology models and third-party models generated through the AlphaFold2 and AlphaFold-Multistate artificial intelligence (AI) methods. Our analysis revealed considerable accuracy for both homology models and AI-generated models. However, it also revealed the general superiority of AI methods. Particularly noteworthy is the model generated by AlphaFold2, which captured with high fidelity various structural aspects, including the challenging second extracellular loop. Our previously published homology model of the GPR101-Gs protein complex, based on the β2-adrenergic receptor, accurately predicted the binding mode of the G protein to the receptor. Moreover, this model predicted the structure of the sixth transmembrane domain (TM6) significantly more accurately than the others, including those built through AI methods, suggesting that homology modeling based on templates solved in complex with the G protein of interest might be the most reliable way of modeling this transmembrane domain. Lastly, our analysis revealed that our molecular dynamics simulations did not have a significant and consistent effect on the accuracy of the models, increasing the accuracy for some domains while decreasing it for others. This work provides insights into the relative strengths of different modeling approaches for our case study on GPR101. More broadly, when considered alongside other assessment studies, it contributes to the growing body of knowledge that can guide the modeling of GPCRs for which experimental structures are not yet available.
Copyright © 2025 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Stefano Costanzi reports financial support was provided by National Institutes of Health. Giampaolo Trivellin reports financial support was provided by Telethon Foundation. Giampaolo Trivellin reports financial support was provided by Italian Ministry of University and Research. Constantine Stratakis reports financial support was provided by Foundation for Research and Technology Hellas. Constantine Stratakis reports financial support was provided by National Institutes of Health. Giampaolo Trivellin reports a relationship with ONO Pharma UK Ltd that includes: consulting or advisory. Constantine Stratakis has working relationships with the ELPEN, SteroTx, and H. Lundbeck A/S pharmaceutical companies, as well as Healthspan Digital, ASTREA Health and Human Longevity corporations. Constantine Stratakis, Giampaolo Trivellin, Stefano Costanzi have patent #WO2022031407A1 "Gpr101 ligands for treating growth hormone-related disorders" pending to U.S. Department of Health and Human Services. Constantine Stratakis, Giampaolo Trivellin have patent #US Patent No. 10,350,273, "Treatment of Hormonal Disorders of Growth" pending to U.S. Department of Health and Human Services. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Similar articles
-
Prescription of Controlled Substances: Benefits and Risks.2025 Jul 6. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. 2025 Jul 6. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. PMID: 30726003 Free Books & Documents.
-
The Black Book of Psychotropic Dosing and Monitoring.Psychopharmacol Bull. 2024 Jul 8;54(3):8-59. Psychopharmacol Bull. 2024. PMID: 38993656 Free PMC article. Review.
-
Sexual Harassment and Prevention Training.2024 Mar 29. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. 2024 Mar 29. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. PMID: 36508513 Free Books & Documents.
-
The Lived Experience of Autistic Adults in Employment: A Systematic Search and Synthesis.Autism Adulthood. 2024 Dec 2;6(4):495-509. doi: 10.1089/aut.2022.0114. eCollection 2024 Dec. Autism Adulthood. 2024. PMID: 40018061 Review.
-
Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19.Cochrane Database Syst Rev. 2022 May 20;5(5):CD013665. doi: 10.1002/14651858.CD013665.pub3. Cochrane Database Syst Rev. 2022. PMID: 35593186 Free PMC article.
References
-
- Trivellin G, Daly AF, Faucz FR, Yuan B, Rostomyan L, Larco DO, Schernthaner-Reiter MH, Szarek E, Leal LF, Caberg J-H, Castermans E, Villa C, Dimopoulos A, Chittiboina P, Xekouki P, Shah N, Metzger D, Lysy PA, Ferrante E, Strebkova N, Mazerkina N, Zatelli MC, Lodish M, Horvath A, de Alexandre RB, Manning AD, Levy I, Keil MF, de la Sierra ML, Palmeira L, Coppieters W, Georges M, Naves LA, Jamar M, Bours V, Wu TJ, Choong CS, Bertherat J, Chanson P, Kamenický P, Farrell WE, Barlier A, Quezado M, Bjelobaba I, Stojilkovic SS, Wess J, Costanzi S, Liu P, Lupski JR, Beckers A, Stratakis CA, Gigantism and Acromegaly Due to Xq26 Microduplications and GPR101 Mutation, N. Engl. J. Med 371 (2014) 2363–2374. 10.1056/NEJMoa140802. - DOI - PMC - PubMed
-
- Bates B, Zhang L, Nawoschik S, Kodangattil S, Tseng E, Kopsco D, Kramer A, Shan Q, Taylor N, Johnson J, Sun Y, Chen HM, Blatcher M, Paulsen JE, Pausch MH, Characterization of Gpr101 expression and G-protein coupling selectivity, Brain Res. 1087 (2006) 1–14. 10.1016/j.brainres.2006.02.123. - DOI - PubMed
-
- Abboud D, Daly AF, Dupuis N, Bahri MA, Inoue A, Chevigné A, Ectors F, Plenevaux A, Pirotte B, Beckers A, Hanson J, GPR101 drives growth hormone hypersecretion and gigantism in mice via constitutive activation of Gs and Gq/11, Nat. Commun 11 (2020) 4752. 10.1038/s41467-020-18500-x. - DOI - PMC - PubMed
-
- Trivellin G, Tirosh A, Hernández-Ramírez LC, Gupta T, Tsai-Morris CH, Faucz FR, Burgess HA, Feldman B, Stratakis CA, The X-linked acrogigantism-associated gene gpr101 is a regulator of early embryonic development and growth in zebrafish, Mol. Cell. Endocrinol 520 (2021) 111091. 10.1016/j.mce.2020.111091. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources